On January 23, 2018, POLUS BioPharm Inc. (KOSE:A007630) closed the transaction. The company announced that it has issued 7,194,244 shares for gross proceeds of KRW 29,999,997,480 in its second tranche. The company received KRW 72,499,997,480 in funding so far in the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
495 KRW | +1.43% | 0.00% | -20.42% |
1st Jan change | Capi. | |
---|---|---|
-20.42% | 21.23M | |
+154.07% | 3,092B | |
+69.48% | 803B | |
+52.59% | 793B | |
+16.60% | 278B | |
+42.26% | 230B | |
+141.12% | 188B | |
+16.62% | 181B | |
+54.21% | 146B | |
-36.28% | 136B |
- Stock Market
- Equities
- A101400 Stock
- News N Citron, Inc.
- POLUS BioPharm Inc. announced that it has received KRW 72.50 billion in funding from NeoFidelity, Inc., Polus Holdings Co., Ltd